Basel Medical Group Income Statement

Financials in millions SGD. Fiscal year is July - June.

Millions SGD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Revenue	11.32	10.05	9.7	10.66
Revenue Growth (YoY)	12.63%	3.60%	-8.98%	-
Cost of Revenue	8.95	5.89	5.58	6.21
Gross Profit	2.37	4.16	4.12	4.45
Selling, General & Admin	0.14	0	0.02	0.01
Depreciation & Amortization Expenses	1.18	0.53	0.56	0.58
Other Operating Expenses	13.65	1.51	1.58	1.71
Total Operating Expenses	14.97	2.04	2.16	2.3
Operating Income	-12.6	2.12	1.96	2.15
Interest Expense	-0.2	-0.18	-0.24	-0.32
Other Non-Operating Income (Expense)	1.75	0.46	0.41	0.55
Total Non-Operating Income (Expense)	1.55	0.28	0.17	0.23
Pretax Income	-11.05	2.4	2.13	2.39
Provision for Income Taxes	-0.42	0.33	-	-
Net Income	-10.64	2.07	1.78	2.39
Minority Interest in Earnings	-0	-	-	-
Net Income to Common	-10.64	2.07	1.78	2.39
Net Income Growth	-	16.23%	-25.27%	-
Shares Outstanding (Basic)	19	16	16	16
Shares Outstanding (Diluted)	19	16	16	16
Shares Change (YoY)	15.60%	-	-	-
EPS (Basic)	-0.57	0.13	0.11	0.12
EPS (Diluted)	-0.57	0.13	0.11	0.12
EPS Growth	-	18.18%	-8.33%	-
Free Cash Flow	-4.6	2.5	2.59	2.7
Free Cash Flow Growth	-	-3.56%	-4.07%	-
Free Cash Flow Per Share	-0.24	0.15	0.16	0.17
Gross Margin	20.93%	41.43%	42.44%	41.74%
Operating Margin	-111.33%	21.09%	20.18%	20.20%
Profit Margin	-93.96%	20.62%	18.38%	22.39%
FCF Margin	-40.64%	24.89%	26.74%	25.37%
EBITDA	-11.42	2.65	2.51	2.73
EBITDA Margin	-100.89%	26.35%	25.92%	25.61%
EBIT	-12.6	2.12	1.96	2.15
EBIT Margin	-111.33%	21.09%	20.18%	20.20%
Effective Tax Rate	3.78%	13.80%	0.00%	0.00%

SEC Filings: 10-K · 10-Q